207940.KS
Samsung Biologics Co.,Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 1,477,000.00
−1.60%Year over year
Reported trailing growth
- Revenue
- -9.6%
- EBITDA
- +31.9%
- EBIT
- +22.2%
- EPS
- +54.4%
- Free cash flow
- +293.1%
- Operating cash flow
- +4.2%
Forward estimates
Based on analyst estimates
- Revenue
- +31.4%
- EBITDA
- +13.5%
- EPS
- +6.2%
Three-year CAGR
- Revenue
- +14.9%
- EBITDA
- +26.3%
- EBIT
- +28.1%
- Net income
- +30.8%
- EPS
- +29.9%
- Free cash flow
- +23.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026